Todd Rosenbluth

Director of ETF and Mutual Fund Research
S&P Capital IQ Equity Research

Todd Rosenbluth is a Senior Director at S&P Capital IQ and is Director of ETF and Mutual Fund Research in the United States, leading the firm’s holdings-based research efforts. He publishes regular thought leadership content on equity and fixed income products, maintains the quantitative fund models and supports client needs. He also serves as a member of Portfolio Strategy Committee, and the Investment Policy Committee.

Todd has been interviewed and quoted numerous times in various newspapers and magazines, including Barron’s, The New York Times, Financial Advisor magazine, The Wall Street Journal and USA Today. He has also been frequently quoted on the Internet at and, and has appeared on Bloomberg and CNBC.

Prior to his current role, Todd was a Group Head and has responsibility for stocks within the telecom services, telecom equipment, electric and gas utilities industries. Todd was named in the 2011 The Wall Street Journal’s Best on the Street Survey for his coverage of telecom services stocks.

Todd previously served in other financial positions at the company such as International Mutual Fund Sector Specialist and Large Cap Value and Large Cap Growth Analyst, as well as serving on the Fund Services Asset Allocation Committee.

Prior to joining S&P in 2001, Todd was managing editor of Value Line Mutual Fund Survey and Senior Large Cap and Small Cap Value Mutual Fund Analyst. He also held the position of Financial Advisor with Morgan Stanley.

In 1997, Todd received a B.G.S in Finance from the University of Michigan and received an MBA in Finance from New York University in 2002.

Author Archives: Todd Rosenbluth

What’s Behind Biotech Gains?

Biotechnology companies comprised 21% of the S&P 500 Health Care Sector index, making it the second largest industry, behind pharmaceuticals (42%), but ahead of health care providers (19%) and health care equipment & suppliers (14%). The industry has been a top performer in recent years, but S&P Capital IQ sees additional catalysts. Biotechnology was the Read more […]

Drivers of Technology ETFs

While S&P Capital IQ consensus forecasts for second quarter 2015 EPS has declined sharply since the beginning of 2015, we think that the information technology sector should be one of the bright spots. Meanwhile, the sector is trading at a discounted P/E multiple. We believe investors can gain exposure to a number of favorable trends Read more […]

Biotech Has More Room to Run

Biotechnology has been one of the best performing industries in the stock market over the past several years. According to S&P Capital IQ, there were numerous catalysts, for this substantial stock outperformance, including several blockbuster drug approvals that drove significant sales and earnings growth. Yet, S&P CIQ thinks the industry’s drivers, including a robust pipeline, Read more […]